Short Interest Report: Codexis Incorporated (NASDAQ:CDXS) Just Reported Increased Shorts

November 29, 2016 - By Darrin Black   ·   0 Comments

Short Interest Report: Codexis Incorporated (NASDAQ:CDXS) Just Reported Increased Shorts

The stock of Codexis Incorporated (NASDAQ:CDXS) registered an increase of 1.21% in short interest. CDXS’s total short interest was 1.17 million shares in November as published by FINRA. Its up 1.21% from 1.15 million shares, reported previously. With 152,200 shares average volume, it will take short sellers 8 days to cover their CDXS’s short positions. The short interest to Codexis Incorporated’s float is 4.71%. The stock decreased 4.00% or $0.2 during the last trading session, hitting $4.8. Codexis, Inc. (NASDAQ:CDXS) has risen 39.13% since April 26, 2016 and is uptrending. It has outperformed by 33.87% the S&P500.

Codexis, Inc. is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The company has a market cap of $197.86 million. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. It currently has negative earnings. The Company’s pharmaceutical products include enzymes, pharmaceutical intermediates, active pharmaceutical ingredients and Codex Biocatalyst Panels and Kits.

Insitutional Activity: The institutional sentiment increased to 1.76 in Q2 2016. Its up 0.34, from 1.42 in 2016Q1. The ratio improved, as 14 funds sold all Codexis, Inc. shares owned while 12 reduced positions. 20 funds bought stakes while 17 increased positions. They now own 16.51 million shares or 13.83% more from 14.50 million shares in 2016Q1.
Jpmorgan Chase & accumulated 786 shares or 0% of the stock. Moreover, Architects has 0% invested in Codexis, Inc. (NASDAQ:CDXS) for 1,000 shares. Tower Research Cap Ltd Limited Liability Company (Trc) last reported 996 shares in the company. Citigroup reported 3,372 shares or 0% of all its holdings. The Massachusetts-based State Street Corporation has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Manufacturers Life Insur The holds 0% or 28,751 shares in its portfolio. Blackrock Mngmt Ltd owns 123,762 shares or 0% of their US portfolio. The New York-based Amer Interest Gp has invested 0% in Codexis, Inc. (NASDAQ:CDXS). Baillie Gifford has 1.19M shares for 0.01% of their US portfolio. Tfs Cap Limited Liability Com accumulated 24,097 shares or 0.02% of the stock. Palisade Capital Nj holds 0.04% or 246,000 shares in its portfolio. California State Teachers Retirement Sys has invested 0% of its portfolio in Codexis, Inc. (NASDAQ:CDXS). Goldman Sachs Gru Inc, a New York-based fund reported 16,937 shares. Nantahala Mngmt Limited Liability Corp accumulated 5.55M shares or 2.42% of the stock. Blackrock Advisors Ltd Liability Corp holds 9,569 shares or 0% of its portfolio.

Insider Transactions: Since August 3, 2016, the stock had 1 buy, and 5 insider sales for $1.26 million net activity. VIVO VENTURES VII – LLC sold $474,624 worth of stock. Yang Patrick Y bought $48,300 worth of stock. WOLF DENNIS P also sold $75,974 worth of Codexis, Inc. (NASDAQ:CDXS) shares. KELLEY BERNARD J also sold $53,807 worth of Codexis, Inc. (NASDAQ:CDXS) shares.

CDXS Company Profile

Codexis, Inc., incorporated on January 31, 2002, is a developer of biocatalysts for the pharmaceutical and fine chemicals markets. The Company’s technologies enable scale-up and implementation of biocatalytic solutions for process development, from research to manufacturing. The Company’s CodeEvolver protein engineering technology platform, which introduces genetic mutations into genes in order to give rise to changes in the enzymes that they produce, overcomes many of the limitations, allowing clients to evolve and optimize biocatalysts to perform specific and desired chemical reactions at commercial scale. The Firm have commercialized its technology and products in the pharmaceuticals market, which is its primary business focus. The Company’s pharmaceutical customers, including several of the global pharmaceutical companies, use its technology, services and products in their manufacturing processes and process development.

Another recent and important Codexis, Inc. (NASDAQ:CDXS) news was published by Marketwatch.com which published an article titled: “Codexis Inc.” on April 22, 2010.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By Darrin Black

Tags: , ,


Readers Comments (0)





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>